CD274 and cancer: For example, to increase the efficacy of PD-1/PD-L1 immunotherapy, it is necessary to design specific antibodies that can recognize the complex N-glycan structure of PD-L1 itself [124], because the complex glycan structure formed by PD-L1 will obscure its conventional antigen epitopes, affect the binding between PD-L1 and anti-PD-L1 monoclonal antibodies, and increase the possibility of immune escape of cancer cells [125].